The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A systematic review and meta-analysis of early death (ED) upon immune checkpoint inhibitors (ICI) alone or combined with other non-ICIs treatments as first-line treatment of advanced solid tumors.
 
Giuseppe Viscardi
No Relationships to Disclose
 
Antonino Carmelo Tralongo
No Relationships to Disclose
 
Michela Cinquini
No Relationships to Disclose
 
Francesco Massari
No Relationships to Disclose
 
Vittorio Simeon
No Relationships to Disclose
 
Matteo Lambertini
Consulting or Advisory Role - AstraZeneca; Exact Sciences; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Seagen
Speakers' Bureau - Ipsen; Knight Therapeutics; Libbs; Lilly; Novartis; Pfizer; Roche; Sandoz; Takeda
 
Salvatore Alfieri
No Relationships to Disclose
 
Veronica Mollica
No Relationships to Disclose
 
Alessandro Rizzo
No Relationships to Disclose
 
Francesca Comito
No Relationships to Disclose
 
Martina Imbimbo
No Relationships to Disclose
 
Carminia Maria Della Corte
Consulting or Advisory Role - MSD
 
Arsela Prelaj
Other Relationship - AstraZeneca; Bristol-Myers Squibb; Roche
 
Diego Signorelli
Other Relationship - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD
 
Claudia Proto
Other Relationship - Bristol-Myers Squibb; MSD
 
Giuseppe Lo Russo
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb/Medarex; italfarmaco; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb/Medarex (Inst); Celgene (Inst); GlaxoSmithKline (Inst); MSD Oncology; MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS; MSD; Roche
 
Fortunato Ciardiello
Consulting or Advisory Role - Amgen; Bayer; Merck KGaA; Pfizer; Roche/Genentech
Research Funding - Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Roche/Genentech (Inst); SERVIER (Inst); Symphogen (Inst)
 
Marina Chiara Garassino
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; MSD Oncology; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Daiiki Sankyo; GlaxoSmithKline; Incyte; Inivata; Janssen; Lilly; MSD; Novartis; Pfizer; Regeneron; Roche; Sanofi; Seagen; Takeda; Tiziana Life Sciences
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Celgene; Incyte; Lilly; MSD Oncology; Otsuka; Roche; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Valter Torri
No Relationships to Disclose
 
Roberto Ferrara
Consulting or Advisory Role - BeiGene; Merck Sharp & Dohme